IJR News

Carly Simon Reveals Parkinson's Disease and Facial Cancer

Iconic singer Carly Simon, 83, revealed she has Parkinson's disease and skin cancer, saying she has been learning to live with the progressive condition after years away from the public eye. She described mobility challenges stemming from arthritis and multiple joint replacements, the Mayo Clinic diagnosis, and indicated she is moving forward with new music, including the upcoming album Comes in Waves.

Carly Simon

Jul 27, 2026

Argenx plans $2.2B Forte Biosciences deal

Argenx has agreed to acquire Forte Biosciences for about $2.2 billion in cash, offering $77 per Forte share and funded entirely from Argenx’s cash to complete a Q3 2026 closing after standard approvals and tender conditions. The deal adds Forte’s FB102, a first-in-class CD122 antibody for vitiligo and celiac disease with potential broader autoimmune applications, boosting Argenx's immunology pipeline beyond Vyvgart.

Forte

Jul 27, 2026

Social Issues

Seattle-area Raccoon Jimothy Draws Attention, Warnings

Public health officials in Seattle and Toronto urged people to admire Jimothy, the viral Seattle raccoon, from a distance and not to touch or feed him, warning that wild animals can carry serious diseases and pose bite or scratch risks. Despite his internet fame and local celebrations, authorities highlighted risks such as raccoon roundworm, leptospirosis, and the potential for rabies in wildlife.

Jul 25, 2026

Baseball

AL West Farm Report Angels Exit Playoff

Across MLB farm systems, July updates show the Angels weighing whether to sell or push for upside with controllable pitchers and highlight rising arms and hitters—while the Dodgers, Diamondbacks, and other NL West clubs emphasize a deep prospect runway and high-end pitching within their pipelines as the trade deadline nears. Outside baseball, South Dakota State University will host a Northeast Research Farm Field Day focusing on practical agronomy topics like variety selection, weed and disease management, and soil nutrient strategies for northeast South Dakota crops.

Jul 25, 2026

Teladoc Health launches Teladoc One virtual care

Teladoc Health unveiled Teladoc One, a 100% risk-based, integrated virtual care model that unifies multidisciplinary care teams with an AI-enabled Pulse data ecosystem to coordinate care across departments and replace fragmented, disease-specific programs. Targeting employers and health plans, the model will launch with cardiometabolic programs in September 2026 and broadly in January 2027, tying payments to clinical and financial outcomes while using care guides, AI triage, and data integration to reduce costs and improve outcomes.

Instacart National Basketball Players Association

Jul 23, 2026

European Union

EU Approves Etcamah in First-Line ER+ Breast Cancer

AstraZeneca’s Etcamah (camizestrant) won EU approval to be used with CDK4/6 inhibitors as a first-line treatment for ER-positive, HER2-negative advanced breast cancer in patients with ESR1 mutations, based on SERENA-6 trial results showing a 56% reduction in progression or death. The drug already has approvals in Japan, the UAE, and Saudi Arabia, with U.S. review ongoing and the EU decision highlighting its potential to expand AstraZeneca’s oncology footprint as it targets endocrine-resistant disease.

United States European Union

Jul 23, 2026

Zydus Lifesciences plans Phase III Desidustat trial sickle cell ICMR

Zydus Lifesciences has received regulatory approval to initiate a 203-day Phase III trial of Desidustat for sickle cell disease in collaboration with ICMR, enrolling 164 patients to assess efficacy and safety of the oral tablet. The move follows successful Phase II results and US FDA Orphan Drug Designation, underscoring a public-private effort to address India's substantial SCD burden.

United States India

Jul 23, 2026

FDA

Monopar Starts Rolling NDA for ALXN1840 Wilson Disease

Monopar Therapeutics has begun a rolling submission of a New Drug Application with the FDA for ALXN1840 to treat Wilson disease, with the first completed sections already filed under a rolling NDA process. The first-in-class albumin tripartite complex activator carries Fast Track, Orphan Drug, and Rare Pediatric Disease designations and aims to become the first novel-mechanism therapy approved for Wilson disease in decades.

FDA

Jul 22, 2026

Markets

Cadrenal Launches Cardiac Acute Care Franchise, Seeks Partners

Cadrenal Therapeutics has reorganized its clinical portfolio into a Cardiac Acute Critical Care Franchise and is launching a structured process to secure strategic out-licensing, portfolio monetization, or commercial co-development partnerships for its late-stage assets, including CAD-1005, frunexian, and tecarfarin. The move aims to maximize asset value through a partnership-driven model, supported by Phase 2 data showing more than a 25% reduction in thrombotic events and by orphan drug designations, with exploration of expanded indications such as Kawasaki disease in pediatrics and broader cardiorenal applications.

Jul 21, 2026

Carly Simon Reveals Parkinson's Disease and Facial Cancer

Argenx plans $2.2B Forte Biosciences deal

Seattle-area Raccoon Jimothy Draws Attention, Warnings

AL West Farm Report Angels Exit Playoff

Teladoc Health launches Teladoc One virtual care

EU Approves Etcamah in First-Line ER+ Breast Cancer

Zydus Lifesciences plans Phase III Desidustat trial sickle cell ICMR

Monopar Starts Rolling NDA for ALXN1840 Wilson Disease

Cadrenal Launches Cardiac Acute Care Franchise, Seeks Partners

More headlines